Antifungal effect of various essential oils against Candida albicans. Potentiation of antifungal action of amphotericin B by essential oil from Thymus vulgaris

Phytotherapy Research

Volumn 18, Issue 12, 2004, Pages 990-995

  Giordani, R ^a,b   Regli, P ^a   Kaloustian, J ^a,c   Mikail C ^a   Abou, L ^a   Portugal, H ^a,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b CNRS and Aix Marseille University   (France)

^c INSERM   (France)

Author keywords

Amphotericin B; Antifungal action; Candida albicans; Essential oils; GC MS

Indexed keywords

AMPHOTERICIN B; CLOVE OIL; ESSENTIAL OIL; LAVANDULA ANGUSTIFOLIA OIL; LAVANDULA HYBRIDA OIL; LAVENDER OIL; LIMONENE; ORIGANUM VULGARE OIL; PHENOL DERIVATIVE; ROSMARINUS OFFICINALIS EXTRACT; SATUREJA MONTANA OIL; SYZYGIUM AROMATICUM OIL; THYME OIL; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CELL MEMBRANE PERMEABILITY; CELL RESPIRATION; CHEMICAL COMPOSITION; CLOVE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG POTENTIATION; FUNGUS GROWTH; GAS CHROMATOGRAPHY; GROWTH INHIBITION; LAVANDULA ANGUSTIFOLIA; LAVANDULA HYBRIDA; LAVENDER; MASS SPECTROMETRY; MEDICINAL PLANT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OREGANO; PHYTOTHERAPY; ROSEMARY; SATUREJA MONTANA; THYME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; PHYTOTHERAPY; PLANT OILS; THYMUS PLANT;

EID: 14044262117     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1594     Document Type: Article

References (23)

1. d'Auria FD, Laino L, Strippoli V, et al. 2001. In vitro activity of tea tree oil against Candida albicans mycelial conversion and other pathogenic fungi. J Chemother 13: 377-383.
2. Bennet JE. 1974. Chemotherapy of systemic mycoses. N Engl J Med 290: 30-32.
3. Bruatto M, Vidotto V, Marinuzzi G, Raiteri R, Sinicco A. 1991. Candida albicans in human immunodeficiency virus type 1-infected patients with oral candidiasis before and after fungal therapy. J Clin Microbiol 29: 726-730.
4. Butler WT, Bennett JE, Alling DW, Wertlake PT, Utz JP, Hill GJ. 1964. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 61: 175-187.
5. Cox SD, Mann CM, Markham JL, et al. 2000. The mode of antimicrobial action of the essential oil of Malaleuca alternifolia (tea tree oil). J Appl Microbiol 88: 170-175.
6. Dupont B, Drouhet E. 1979. In vitro synergy and antagonism of antifungal agents against yeast-like fungi. Postgrad Med J 55: 683-686.
7. Fan-Havard P, Capano D, Smith SM, Mangia A, Eng RHK. 1991. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother 35: 2302-2305.
8. Giordani R, Buc J, Regli P. 2002a. Mathematical modelling of antifungal action. Mycoses 45: 482-487.
9. Giordani R, Gachon C, Regli P, Jacob JL. 1999. Antifungal action of Hevea brasiliensis latex. Its effect in combination with fluconazole on Candida albicans growth. Mycoses 42: 465-474.
10. Giordani R, Majeri M, Regli P, Buc J. 2003a. Increasing antifungal action of ketoconazole by Hevea brasiliensis latex and involvement of rubber particles in this fungistatic effect against Candida albicans. J Mycol Med 13: 24-28.
11. Giordani R, Regli P, Buc J. 2002b. Antifungal effect of Hevea brasiliensis latex with various fungi. Its synergistic action with amphotericin B against Candida albicans. Mycoses 45: 476-481.
12. Giordani R, Regli P, Kaloustian J, Portugal H, Buc J. 2003b. In vitro synergistic effect of a mixture of Hevea brasiliensis latex and essential oil from Thymus vulgaris with amphotericin B against Candida albicans. J Mycol Med 13: 87-91.
13. Giordani R, Siepaio M, Regli P. 1991. Antifungal action of Carica papya latex: isolation of fungal hydrolysing enzymes. Mycoses 34: 469-477.
14. Guillaume MP, De Prez C, Cognan E. 1996. Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolong fluconazole administration. Am J Gastroenterol 91: 165-168.
15. Holmberg K, Meyer MD. 1986. Fungal infections in patients with AIDS and AIDS-related complex. Scand J Infect Dis 18: 179-192.
16. Hudaib M, Speroni E, Di Pietra AM, Cavrini V. 2002. GC/MS evaluation of thyme (Thymus vulgaris L.) oil composition and variations during the vegetative cycle. J Pharm Biochem Analys 29: 691-700.
17. Kishore N, Mishra AK, Chansouria JPN. 1993. Fungitoxicity of essential oils against dermatophytes. Mycoses 36: 211-215.
18. Knobloch K, Pauli A, Iberl B, Weigand H, Weis N. 1989. Antibacterial and antifungal properties of essential oil components. J Essent Oil Res 1: 119-128.
19. Korting HC, Ollert M, Georgii A, Fröschl M. 1988. In vitro susceptibilities and biotypes of Candida albicans isoltes from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol 26: 2626-2631.
20. Maudsley F, Kerr KG. 1999. Microbiological safety of essential oils used in complementary therapies and activity of these compounds against bacterial and fungal pathogens. Support Care Cancer 7: 100-102.
21. Moulin-Traffort J, Giordani R, Regli P. 1990. Antifungal action of latex saps from Lactuca sativa and Asclepias curassavica. Mycoses 33: 383-392.
22. Siau H, Kerridge D. 1998. The effect of antifungal drugs in combination on the growth of Candida glabrata in solid and liquid media. J Antimicrob Chemother 41: 357-366.
23. Viollon C, Chaumont JP. 1994. Antifungal properties of essential oils and their main components upon Crytococcus neoformans. Mycopathologia 128: 151-153.